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Abstract 
Based on our earlier research into the main characteristics and risk factors for infections in 
hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for 
Risk of Infection (MMIRI) to predict infection in myeloma patients. The included factors that could 
influence the pathogenesis and incidence of infections were sex, performance status, Durie Salmon 
stage of disease, International Staging System, serum creatinine level, immune paresis, neutropenia, 
serum ferritin level, the presence of any catheters, disease duration, stable/progressive disease, and 
type of therapy. For each of these parameters, the strength of association with infection was 
statistically estimated and specific number of points was assigned to each of these parameters, 
proportional to the strength of the association. When designing the MMIRI, we included only those 
parameters that we determined were pathophysiologically associated with the infection. After 
further statistical analysis, we identified an optimal cutoff score of 6 or above as indicating a 
significant risk for infection, with a sensitivity of 93.2% and specificity of 80.2%. The scoring system 
in the retrospective receiver operating characteristic analysis showed an area under the curve of 
0.918. The potential value of the MMIRI is the possibility of identifying those patients who would 
benefit from the prophylactic administration of antibiotics and other anti-infective measures while 
minimizing the contribution to antibiotic resistance related to the overuse of these drugs. As far as 
we know, this index represents the first attempt to create such an instrument for predicting the 
occurrence of infections in myeloma patients. 
  
Introduction 
 The intrinsic immune dysfunction in 
combination with therapy-related immunosup-
pression leads to an increased risk for infections, 
which is a hallmark of multiple myeloma (MM) and 
major cause of mortality [1-5]. Furthermore, the 
infection itself can pathogenetically contribute to the 
progression of MM through different mechanisms, 
such as robust production of promyeloma cytokines 
(e.g., interleukin-6) and activation of Toll-like 
receptors on malignant plasma cells [6-10]. Today, 
with the advent of several new and effective 
antimyeloma drugs and increased overall survival, 
preventing death from infections becomes 
paramount. We tried to create the numerical Multiple 
Myeloma Index for Risk of Infection (MMIRI) to 
predict infection in myeloma patients and help 
identify patients who have a higher risk for 
developing infections.  
Materials and Methods  
To develop the index, we used our earlier 
research into the main characteristics and risk factors 
for infections in hospitalized patients with MM [11]: 
we took retrospective data from hospital medical 
documentation for 240 cases of hospitalized patients 
with MM (120 males and 120 females; average age of 
69, range of 41-89 years) who were diagnosed or 
treated in our Department from January 2008 to 
December 2010. Because the majority of patients were 








cases was larger than the number of patients included 
in this study (37 males and 35 females, respectively). 
Only patients who were not treated with autologous 
or allogeneic hematopoietic stem cell transplant were 
included. The diagnosis was established according to 
International Myeloma Working Group criteria [12]. 
The great majority of patients in this study had IgG, 
IgA, or a light-chain myeloma; however, one patient 
with IgD and one with nonsecretory myeloma were 
also included [11]. Our patients were treated fairly 
uniformly at the time of this study: vincristine, 
doxorubicin, and dexamethasone and oral melphalan 
and prednisone regimens were mostly used as 
induction therapy (according to patient age and 
eligibility for high-dose therapy), with 
thalidomide-based protocols as second-line therapy 
and bortezomib-based protocols as third- or next-line 
therapy. In some patients, monotherapy with 
dexamethasone was used as a front-line therapy, as 
well as for postinduction [11]. The study was 
approved by the Medical School of Rijeka Ethics 
Committee.  
The criteria for infection used in our study were 
increased body temperature above the normal range 
(37 °C) or isolation of a microbial agent in patients 
who also had concomitant clinical symptoms and/or 
humoral signs of infection (leukocytosis, neutrophilia, 
marked “left shift,” or increased C-reactive protein in 
comparison with a baseline value) [11]. The included 
factors that could influence the pathogenesis and 
incidence of infections were sex, performance status 
[13], Durie Salmon stage of disease [14], International 
Staging System [15], serum creatinine level (normal or 
increased), immune paresis defined qualitatively 
(decreased serum concentration of any polyclonal Ig 
class), neutropenia (defined as blood neutrophil count 
of ≤2×109/L), serum ferritin level (normal; moderately 
increased; extremely increased), the presence of any 
catheters, disease duration, stable/progressive 
disease, and type of therapy. The number of cases, 
age, sex, and duration of disease for MM patients with 
and without infections are presented in Table 1. The 
characteristics of tested parameters are shown in 
Table 2 [11]. 
For each of these parameters, the strength of 
association with infection was statistically estimated. 
When designing the MMIRI, we included only those 
parameters that we determined were 
pathophysiologically associated with the infection. A 
specific number of points was assigned to each of 
these parameters, proportional to the strength of the 
statistical association. Statistical association between 
nominal variables was measured by Cramer’s V 
coefficient, whereby a minimum coefficient value of 
0.15 was required. For the scoring system, the 
coefficient values were divided by a minimum value 
and rounded to the nearest integer. The cutoff value 
of the scoring system was determined by optimization 
of sensitivity and specificity based on the Youden 
index together with classical receiver operating 
characteristic analysis.  
 
Table 1. Main cases characteristics  
  With infections  Without infections  Total  
Number of cases  43  197  240  
Age, median (range)  65 (41–89)  69 (41–86)  69 (41–89)  
Sex (male/female), n  9/34  111/86  120/120  
Disease duration 
(months), median (range)  
26 (1–121)  7 (1–150)  8 (1–150)  
 
 
Table 2. Characteristics of tested parameters 








Sex Male 120 111 9 




0 16 16 0 
1 88 85 3 
2 70 60 10 
3 45 30 15 
4 20 5 15 
Durie-Salmon 
stage of disease 
1A 6 5 1 
2A 51 47  4 
2B 1 0 1 
3A 106 89 17 




1 54 44 10 
2 57 50 7 
3 98 81 17 
Serum 
creatinine level 
≤100 mmol/L (f); ≤120 mmol/L 
(m) (normal value) 
133 117 16 
>100≤175 mmol/L (f); >120≤175 
mmol/L (m)  
52 41 11 
>175 mmol/l (f, m) 49 35 14 
Immuneparesis Yes 184 148 36 
No 46 40 6 
 
Neutropenia 
No 160 138 22 
1.01-2x109/L 55 44 11 
0.51-1x109/L 14 8 6 
<0.5x109/L 3 1 2 
Serum ferritin 
level 
≤120 μg/L (f); ≤300 μg/L (m) 51 46 5 
>120≤240 μg/L (f); > 300≤600 
μg/L (m) 
19 16 3 
>240 μg/L (f); >600 μg/L (m) 32 18 14 
Types of 
therapy 
Without therapy 39 32 7 
VAD 76 71 5 
MP 13 11 2 
Thalidomide-based 20 17 3 
Dexamethasone 55 48 7 
Bortezomib-based 28 14 14 
Others 5 1 4 
Presence of any 
catheters 
Without catheters 190 179 11 
UC 32 22 10 
CVC 2 2 0 
UC, CVC, ITC 2 0 2 
CVC, ITC 1 1 0 
UC, CVC 8 0 8 
f: female, m: male; VAD: vincristine, doxorubicin, dexamethasone, MP: oral 
melphalan and prednisone, UC: urinary catheter, CVC: central venous 
catheter,  ITC: intrathoracic catheter 
 





We provide the relevant parameters associated 
with infections in the statistical analysis and the 
corresponding number of points assigned in the 
MMIRI in Table 3. Some other parameters, such as 
immune paresis and the International Staging System, 
showed no association with infections, and the 
parameters of sex and type of therapy were excluded 
from further analysis based on our determination that 
they were not useful. With these adjustments, we 
identified an optimal cutoff score of 6 or above as 
indicating a significant risk for infection, with a 
sensitivity of 93.2% and specificity of 80.2%. The 
scoring system in the retrospective receiver operating 
characteristic analysis showed an area under the 
curve of 0.918 (p<0.0001; Figure 1). 
 
Table 3. Parameters associated with infections included in the 
MMIRI point system with corresponding points assigned for each 
parameter  
Parameter  Cramer V coefficient  Points  
Longer duration of disease  
 (>8 months)  
0.2326  2  
Durie Salmon Clinical  
Stage 3B  
0.1975  1  
ECOG0 and 1  -0.2935  -2  
ECOG2  -0.0671  0  
ECOG3  0.1862  1  
ECOG4  0.4416  3  
Presence of catheter  0.6539  5  
Elevated creatinine value  0.1545  1  
Moderately elevated ferritin 
value:  
>120 to ≤240 μg/L (f)  
>300 to ≤600 μg/L (m)  
0.3012  2 
Extremely elevated ferritin value:  
>240 μg/L (f)  
>600 μg/L (m)  
0.3834  3  
Neutropenia  0.1418  1  
Progressive disease  0.3206  2  
 
 
Figure 1. Testing of MMIRI by determining its sensitivity and specificity 
Discussion  
The proposed index was created based on 
retrospective data from our specific hospital 
environment. As noted, the parameter of sex was 
excluded from further analysis; based on our findings, 
its association with infections in our sample was 
indirect because of its link with the other 
infection-relevant factors already incorporated into 
the MMIRI (e.g., the women included in our research 
more often had a certain kind of catheter). The 
parameter of type of therapy was also excluded 
because some regimens used at the time of our study 
are now obsolete, and the type and sequence of drugs 
and regimens used today are somewhat different. So 
far, it is well known that some therapies may be 
associated with the occurrence of infections (e.g. 
herpes zoster in patients treated with proteasome 
inhibitors or high-dose dexamethasone, for which 
effective antiviral prophylaxis is mandatory). Some 
recent papers show a possible association of some 
novel drugs with infection [16-25]. Thus, a possible 
causative link between certain drugs and infection 
occurrence must be investigated in further clinical 
studies, and the results can be incorporated into a 
subsequent modification of the proposed index.  
Because transplanted patients were excluded, 
this index can be applied only to those patients who 
are not in the process of hematopoietic stem cell 
transplant or just post transplantation. Nevertheless, 
we believe that this index has great potential to help 
identify patients who have a higher risk for 
developing infections and to improve outcomes for 
myeloma patients. According to the present results, 
the patients with score of 6 or above are candidates for 
mandatory antimicrobial prophylaxis, which is the 
main message of this research. MMIRI and the total 
score can facilitate decision making about the timing 
of antimicrobial prophylaxis and other anti-infective 
measures (e.g., immunoglobulin, granulocyte growth 
factors). This index was created based on 
retrospective data, and our next step is to test it 
prospectively with a larger group of patients treated 
with currently used anti-myeloma drugs and 
regimens.  
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